Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer.
Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, Dennis J, Lush M, Kalari KR, Goetz MP, Wang L, Cairns J, Weinshilboum R, Shepherd L, Chen BE, Häberle L, Ruebner M, Beckmann MW, He W, Larson NL, Armasu SM, Schroth W, Chowbay B, Khor CC, Abubakar M, Antoniou AC, Brüning T, Castelao JE, Chang-Claude J, Nbcs Collaborators, Dörk T, Eccles DM, Figueroa JD, Gago-Dominguez M, García-Sáenz JA, Gündert M, Hack CC, Hamann U, Han S, Hooning MJ, Huebner H, Abctb Investigators, John EM, Ko YD, Kristensen VN, Linn S, Margolin S, Mavroudis D, Nevanlinna H, Neven P, Obi N, Park-Simon TW, Pylkäs K, Rashid MU, Romero A, Saloustros E, Sawyer EJ, Tapper WJ, Tomlinson I, Wendt C, Winqvist R, Dunning AM, Simard J, Hall P, Pharoah PDP, Schwab M, Couch FJ, Czene K, Fasching PA, Easton DF, Schmidt MK, Ingle JN, Brauch H.
Hoppe R, et al. Among authors: pylkas k.
NPJ Breast Cancer. 2025 Feb 19;11(1):18. doi: 10.1038/s41523-025-00733-y.
NPJ Breast Cancer. 2025.
PMID: 39971965
Free PMC article.